Tailoring treatment strategies for NRF2-driven lung cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1138275

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Lung cancer is the fifth most commonly diagnosed cancer and the most common cause of cancer-related death in Australia. Mutations in the KEAP1 gene are observed in a high number of lung cancer patients. These abnormalities are associated with poor prognosis, but may also present an opportunity to specifically target these cancer cells. We will utilise preclinical models to identify new personalised treatment strategies for patients that carry KEAP1 mutations.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $923,501.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

immunotherapy | lung cancer | mouse models | signalling pathways | targeted therapy

Related Links